



[Go to Product page](#)

Datasheet for ABIN730008
anti-GLP-1 antibody (AA 1-31) (Cy5.5)

Overview

| | |
|----------------------|---------------------------------------------------------------------------------------------------------|
| Quantity: | 100 µL |
| Target: | GLP-1 |
| Binding Specificity: | AA 1-31 |
| Reactivity: | Human, Rat, Mouse |
| Host: | Rabbit |
| Clonality: | Polyclonal |
| Conjugate: | This GLP-1 antibody is conjugated to Cy5.5 |
| Application: | Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p)) |

Product Details

| | |
|-------------------|------------------------------|
| Immunogen: | KLH conjugated GLP-1 peptide |
| Isotype: | IgG |
| Cross-Reactivity: | Human, Mouse, Rat |
| Purification: | Purified by Protein A. |

Target Details

| | |
|-------------------|-------------------------------------------|
| Target: | GLP-1 |
| Alternative Name: | GLP-1 (GLP-1 Products) |
| Background: | Synonyms: GLP1, GLP2, GRPP, Glucagon, GCG |

Target Details

Background: Glucagon plays a key role in glucose metabolism and homeostasis. Regulates blood glucose by increasing gluconeogenesis and decreasing glycolysis. A counterregulatory hormone of insulin, raises plasma glucose levels in response to insulin-induced hypoglycemia. Plays an important role in initiating and maintaining hyperglycemic conditions in diabetes. GLP-1 is a potent stimulator of glucose-dependent insulin release. Play important roles on gastric motility and the suppression of plasma glucagon levels. May be involved in the suppression of satiety and stimulation of glucose disposal in peripheral tissues, independent of the actions of insulin. Have growth-promoting activities on intestinal epithelium. May also regulate the hypothalamic pituitary axis (HPA) via effects on LH, TSH, CRH, oxytocin, and vasopressin secretion. Increases islet mass through stimulation of islet neogenesis and pancreatic beta cell proliferation. Inhibits beta cell apoptosis. GLP-2 stimulates intestinal growth and up-regulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. The gastrointestinal tract, from the stomach to the colon is the principal target for GLP-2 action. Plays a key role in nutrient homeostasis, enhancing nutrient assimilation through enhanced gastrointestinal function, as well as increasing nutrient disposal. Stimulates intestinal glucose transport and decreases mucosal permeability. Oxyntomodulin significantly reduces food intake. Inhibits gastric emptying in humans. Suppression of gastric emptying may lead to increased gastric distension, which may contribute to satiety by causing a sensation of fullness. Glicentin may modulate gastric acid secretion and the gastro-pyloro-duodenal activity. May play an important role in intestinal mucosal growth in the early period of life.

Gene ID: 2641

UniProt: [P01275](#)

Application Details

Application Notes: IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 µg/µL

Handling

| | |
|--------------------|--------------------------------------------------------------------------------------------------------------------|
| Buffer: | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol. |
| Preservative: | ProClin |
| Precaution of Use: | This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only. |
| Storage: | -20 °C |
| Storage Comment: | Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Expiry Date: | 12 months |